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Purpose: To evaluate the frequency and clinical impact of switches in antiplatelet therapy 
following implementation of CYP2C19 genotyping after percutaneous coronary intervention 
(PCI). 
Methods: The frequency of escalation (clopidogrel switched to prasugrel/ticagrelor) and de-
escalation (prasugrel/ticagrelor switched to clopidogrel) was evaluated in 1063 PCI patients who 
underwent CYP2C19 genotyping. Risk of major adverse cardiovascular or cerebrovascular 
(MACCE) and bleeding events over one-year was evaluated.  
Results: Antiplatelet therapy switches were common (19%), with escalation (101/115: 88%) and 
de-escalation (77/84: 92%) occurring predominantly in patients with and without a CYP2C19 
nonfunctional allele, respectively. Nonfunctional allele carriers initiated and continued on 
clopidogrel had a significantly higher risk of experiencing either a MACCE or bleeding event 
compared to those escalated to prasugrel/ticagrelor (52 vs. 19 events/100 patient-years; adjusted 
hazard ratio [HR] 2.89 [1.44-6.13], p=0.003). Patients without a nonfunctional allele de-
escalated to clopidogrel had no difference in risk compared to those initiated and continued on 
prasugrel/ticagrelor (21 vs. 19 events/100 patient-years; adjusted HR 1.13 [0.51- 2.34], p=0.751). 
Conclusions: CYP2C19-guided escalation and de-escalation is common in a real-world setting. 
Continuation of clopidogrel in nonfunctional allele carriers is associated with adverse outcomes. 
De-escalation to clopidogrel in patients without a nonfunctional allele appears safe and warrants 





Over 480,000 percutaneous coronary interventions (PCIs) are performed annually in the United 
States.1 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or 
ticagrelor) is indicated after PCI for one year.2 Clopidogrel is a prodrug that requires 
bioactivation by the CYP2C19 enzyme; however, CYP2C19 nonfunctional (*2 and *3) 
polymorphisms are common and significantly impair clopidogrel active metabolite formation, 
platelet inhibition, and clinical effectiveness.3,4 In contrast, prasugrel and ticagrelor exhibit more 
potent and consistent antiplatelet effects, and superior efficacy in acute coronary syndrome 
(ACS) patients, compared to clopidogrel.5,6 Moreover, CYP2C19 genotype does not impact the 
clinical response to prasugrel or ticagrelor.7,8 However, these alternative therapies have higher 
bleeding risk, discontinuation rates, and cost compared to clopidogrel.5,6,9,10  
 
In clinical practice, switching between P2Y12 inhibitors has become increasingly common and is 
driven by clinical and socioeconomic factors.11,12 Understanding the frequency and reasons for 
switching from clopidogrel to prasugrel or ticagrelor (termed “escalation”) or from prasugrel or 
ticagrelor to clopidogrel (termed “de-escalation”) has emerged as a major area of 
investigation.13–18 Notably, accumulating data demonstrate that use of genotyping to guide 
escalation from clopidogrel to prasugrel/ticagrelor in CYP2C19 nonfunctional allele carriers after 
PCI lowers the risk of atherothrombotic events compared with conventional treatment strategies 
without significantly increasing bleeding risk.19–21 Multiple institutions have successfully 
implemented CYP2C19-guided antiplatelet therapy into clinical workflows.22 Given that 
genotype tests are typically ordered reactively, with results obtained after PCI, CYP2C19-guided 





Clinical practice guidelines now recommend preferential use of prasugrel or ticagrelor in ACS 
patients undergoing PCI,2 though clopidogrel remains the most widely prescribed P2Y12 inhibitor 
and the only agent indicated for PCI in the setting of stable disease.9 As a consequence, use of 
prasugrel or ticagrelor early after PCI, when the risk for ischemic events is highest, followed by 
de-escalation to clopidogrel maintenance therapy to reduce bleeding risk and lower medication 
costs has become more common in practice;11,12,23 however, the safety and effectiveness of 
empiric de-escalation remains unclear and studies have yielded conflicting results.16,24 
Biomarker-guided strategies offer the potential to more precisely direct de-escalation and 
improve clinical outcomes.25 Thus, use of CYP2C19 genotyping to guide de-escalation from 
prasugrel/ticagrelor to clopidogrel in patients without a nonfunctional allele has emerged as a 
new paradigm in genotype-guided antiplatelet therapy. 
 
The frequency and timing of CYP2C19 genotype-guided de-escalation of antiplatelet therapy in a 
real-world setting have not been evaluated, and the impact on clinical outcomes is unknown. The 
study objectives were to: (1) describe the frequency and timing of switches between P2Y12 
inhibitors following implementation of a genotype-guided treatment algorithm, (2) evaluate the 
impact of CYP2C19 results on P2Y12 inhibitor escalation and de-escalation, and (3) examine the 









Study Design and Population. A clinical algorithm for CYP2C19 genotype-guided antiplatelet 
selection following PCI in high-risk patients (defined as ACS or high-risk coronary anatomy) 
was implemented at the University of North Carolina-Chapel Hill (UNC), as described.26,27 This 
single-center observational cohort study included 1493 consecutive patients ≥18 years of age 
who underwent coronary artery stent placement at UNC Medical Center from 7/1/2012– 
12/31/2014 and received P2Y12 inhibitor treatment. The investigation was approved by the UNC 
Biomedical Institutional Review Board. Since data was retrospectively abstracted from the 
electronic health record (EHR), informed consent was not required.  
Initial antiplatelet therapy was selected based on clinical factors, and CYP2C19 genotype 
tests were ordered at the interventional cardiologist’s discretion. Clinical testing for the 
CYP2C19*2, *3, and *17 alleles was performed by the UNC Molecular Genetics Laboratory, 
with return of results in the EHR, as described.26,27 Metabolizer phenotypes were assigned 
according to Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations: 
ultrarapid (UM; *17/*17), rapid (RM; *1/*17), normal (NM; *1/*1), intermediate (IM; *1/*2, 
*1/*3, *2/*17, *3/*17), or poor (PM; *2/*2, *2/*3, *3/*3).28 Prasugrel or ticagrelor was 
recommended in nonfunctional allele carriers (IMs and PMs); however, the decision to continue 
the initial agent or switch agents, and the time to switch after PCI, was left to prescriber 
discretion (Figure S1). 
 
Data Abstraction and Study Endpoints. Clinical and medication data, and CYP2C19 genotype 
results, were abstracted from the EHR, as described.26 Initial therapy was defined as the P2Y12 




prescribed over the course of follow-up after any switches. A switch, which included escalation 
(clopidogrel switched to prasugrel/ticagrelor) or de-escalation (prasugrel/ticagrelor switched to 
clopidogrel), was defined as a change occurring after administration of the initial agent. Time-to-
switch was calculated as the number days between the PCI procedure and the date of escalation 
or de-escalation. Elevated risk for bleeding was a composite variable defined as the presence of 
one or more risk factors for bleeding on antiplatelet therapy: age ≥75 years; weight <60 kg; 
previous transient ischemic attack (TIA) or cerebrovascular accident (CVA); history of a 
clinically significant bleeding event; end-stage renal disease requiring dialysis; or, anticoagulant 
prescribed at discharge 
The primary clinical outcome was the composite of either a major adverse cardiovascular 
or cerebrovascular event (MACCE) or clinically significant bleeding event, similar to clinical 
trials of precision antiplatelet therapy.25,29 MACCE and clinically significant bleeding events 
were also analyzed individually as secondary outcomes. MACCE was defined as the composite 
of death, myocardial infarction (MI), stent thrombosis, hospitalization for unstable angina, 
ischemic stroke, or TIA, as described.26 Clinically significant bleeding was defined as GUSTO 
(Global Use of Strategies to Open Occluded Arteries) moderate (requiring blood transfusion but 
not resulting in hemodynamic compromise) or severe/life-threatening (intracerebral hemorrhage 
or bleeding resulting in hemodynamic compromise requiring treatment) bleeding.30 Events were 
identified using physician-reported diagnoses abstracted from the EHR, and verified by an 
interventional cardiologist. Maintenance therapy at the time of event was recorded. 
 
Statistical Analysis. Data are presented as mean±standard deviation, median [interquartile 




(IM/PM or UM/RM/NM) and indication for PCI (ACS or non-ACS/elective) were dichotomized, 
and demographic and clinical factors were compared across groups using Student’s t-test, chi-
square, or Fisher’s exact test. Time-to-switch data were not normally distributed, and compared 
across groups by Wilcoxon signed rank test. Associations between CYP2C19 status and PCI 
indication with switches in therapy were evaluated by logistic regression. 
The time to occurrence of a clinical event within 12 months after PCI (baseline) was 
calculated in each patient that underwent CYP2C19 testing with follow-up information available 
in the EHR after the index PCI admission (n=928). Patients that did not present to UNC for 
outpatient or emergent care after discharge were considered lost to follow-up. Patients that did 
not experience an event were censored at the time of last encounter in which treatment with a 
P2Y12 inhibitor was documented. Event rates were reported as the number of events per 100 
patient-years of follow-up.  
The relationship between P2Y12 inhibitor maintenance therapy, CYP2C19 status, and 
time to occurrence of the primary and secondary clinical outcomes was evaluated by Cox 
proportional hazards regression, as previously described.19,26 Due to the observational study 
design, analyses were completed after adjusting for baseline covariates that associated with 
clinical outcome or differed across CYP2C19-antiplatelet groups. Multivariable models for 
MACCE and bleeding were created using stepwise selection of candidate covariates, described 
in Table S1, with the criterion of P<0.20 to enter and stay in the model. Demographic factors 
(age, gender, African-American race) and clinical factors known to influence antiplatelet therapy 
selection (ACS indication for PCI, elevated risk for bleeding)26 were forced into each model. 
Covariates in adjusted model for MACCE were age (continuous), gender, African-American 




peripheral vascular disease, atrial fibrillation, current smoker, drug-eluting stent at index PCI, 
and discharge statin. Covariates in adjusted model for bleeding were age (continuous), gender, 
African-American race, elevated risk of bleeding (composite), ACS indication for PCI, prior 
stent, drug-eluting stent at index PCI, and multiple vessels stented. The adjusted model for the 
composite MACCE or bleeding outcome included each covariate from the individual MACCE 
and bleeding models.  
In order to examine the impact of genotype-guided escalation and de-escalation, 
associations between CYP2C19-antiplatelet groups (IM/PM-clopidogrel, IM/PM 
prasugrel/ticagrelor, UM/RM/NM-clopidogrel, UM/RM/NM-prasugrel/ticagrelor) and outcome 
were evaluated by Cox proportional hazards regression following stratification by initial 
antiplatelet therapy (clopidogrel: n=612; alternative: n=316). Covariate adjusted hazard ratio 
(HR) and 95% confidence intervals (CIs) for each between-group comparison were calculated. 
Secondary analyses were completed in the strata of patients presenting with an ACS indication 
for PCI. Kaplan-Meier curves were generated using Prism 7.0 (GraphPad Software, La Jolla. 
CA). Analyses were performed using SAS-JMP 12.0 and SAS 9.4 (SAS Institute, Cary, NC). P-
values <0.05 were considered statistically significant.  
A sample size of n=600 initiated on clopidogrel was estimated to provide 80% power to 
detect a HR ≥2.54 (alpha=0.05, two-sided) when comparing IM/PMs continued on clopidogrel 
versus IM/PMs escalated to alternative therapy (nQuery 8.2, Boston, MA), assuming 30% 
IM/PM prevalence, 50% of IM/PMs escalated to prasugrel/ticagrelor (n=90/group), and a 20% 







Study Population. The mean age was 63±12 years, 67.5% were male, and 20.1% were African-
American. Comorbidities such as hypertension (84.3%), diabetes (42.5%), and atrial fibrillation 
(9.9%) were common. Overall, 54.3% underwent PCI for ACS, and 39.2% exhibited a risk factor 
for bleeding. Baseline characteristics are summarized in Table S1.  
Clopidogrel (71.4%) was the most commonly prescribed initial P2Y12 inhibitor, followed 
by prasugrel (27.5%) and ticagrelor (1.1%). Numerous clinical factors differed across initial 
therapy (Table S1). Most notably, a significantly greater proportion initiated on 
prasugrel/ticagrelor had an ACS indication compared to clopidogrel (70.5% vs. 47.8%, 
respectively, P<0.001), whereas significantly fewer initiated on prasugrel/ticagrelor exhibited 
elevated bleeding risk compared to clopidogrel (17.1% vs. 48.0%, respectively, P<0.001). 
 
Genotype Testing and Maintenance Therapy Selection. CYP2C19 genotype was obtained in 
1063 (71.2%) of PCI patients, with results available, on average, 1 day after PCI (Table S2). A 
genotype was more frequently obtained in patients with an ACS compared to a non-ACS/elective 
indication for PCI (78.3% vs. 62.8%, respectively, p<0.001). Among genotyped patients, 329 
(31.0%) carried either one (IM: 303, 28.5%) or two (PM: 26, 2.4%) nonfunctional alleles, and 
450 (42.3%), 239 (22.5%), and 45 (4.2%) were classified as a CYP2C19 NM, RM, and UM, 
respectively. The *2, *3, and *17 allele frequencies were 0.166, 0.001, and 0.183, respectively, 
and did not deviate from Hardy-Weinberg equilibrium (P>0.05 for each allele). 
Overall, clopidogrel (62.2%) was the most commonly prescribed maintenance therapy. 
CYP2C19 IM/PMs were more frequently prescribed prasugrel/ticagrelor than UM/RM/NMs 




alternative therapy. Frequency of alternative therapy use in IM/PMs was significantly higher in 
ACS compared to non-ACS/elective patients (75.5% vs. 59.1%, p=0.002) (Table S2). 
 
Changes in P2Y12 Inhibitor Therapy. P2Y12 inhibitor escalation or de-escalation was observed 
in 209 (14.0%) of all PCI patients. Switches in therapy were significantly more frequent in 
patients with (18.7%) versus without (2.3%) an available CYP2C19 genotype (OR 9.7, 95% CI 
5.1-18.5; p<0.001). In genotyped patients, both escalation from clopidogrel to 
prasugrel/ticagrelor (10.8%) and de-escalation from prasugrel/ticagrelor to clopidogrel (7.9%) 
was common (Figure 1A). Switches in therapy were also more frequent in ACS compared to 
non-ACS/elective patients (22.0% vs. 13.8%, respectively; OR 1.8, 95% CI 1.3- 2.5; p<0.001). 
This difference was primarily driven by higher frequency of de-escalation to clopidogrel (10.7% 
vs. 3.7%, respectively, p<0.001), since no difference in escalation frequency across ACS status 
was observed (11.3% vs. 10.0%, respectively, p=0.505) (Table S2). 
Consistent with genotype-guided prescribing, escalation to prasugrel/ticagrelor occurred 
almost exclusively in IM/PMs (OR 22.8, 95% CI 12.8-40.6, p<0.001), and de-escalation to 
clopidogrel occurred primarily in UM/RM/NMs (OR 5.4, 95% CI 2.5-11.8, p<0.001) (Figure 
1B). Among IM/PMs initiated on clopidogrel, 101 (51.0%) were escalated to prasugrel/ticagrelor 
and 97 (49.0%) were continued on clopidogrel. Among UM/RM/NMs initiated on 
prasugrel/ticagrelor, 77 (32.8%) were de-escalated to clopidogrel and 158 (67.2%) were 
continued on prasugrel/ticagrelor. 
 
Clinical Outcomes. During a median follow-up of 9.2 [4.7–11.1] months, 124 (13.4%) 




to examine the clinical impact of genotype-guided escalation and de-escalation, outcomes were 
evaluated following stratification by initial therapy (Figure 2A). In patients initiated on 
clopidogrel (Table S3) or prasugrel/ticagrelor (Table S4), most baseline characteristics were 
similar across CYP2C19-maintenance therapy groups. However, clopidogrel was more 
frequently used as maintenance therapy in patients with bleeding risk factors.  
In patients initiated on clopidogrel, continuation of clopidogrel in IM/PMs was associated 
with a significantly higher risk of experiencing either a MACCE or bleeding event compared to 
IM/PMs escalated to alternative therapy (51.8 vs. 19.4 events per 100 patient-years, respectively; 
adjusted HR 2.89, 95% CI 1.44-6.13, p=0.003) (Figure 2B; Table 1). In contrast, no significant 
difference was observed in UM/RM/NMs continued on clopidogrel compared to IM/PMs 
escalated to alternative therapy (adjusted HR 1.37, 95% CI 0.76-2.70, p=0.304). Differences in 
risk for MACCE were responsible for the observed association since IM/PMs continued on 
clopidogrel exhibited a significantly higher risk of MACCE compared to IM/PMs escalated to 
alternative therapy (adjusted HR 5.72, 95% CI 2.41-15.81, p<0.001). In contrast, no significant 
differences in risk of clinically significant bleeding events was observed across groups (Table 1, 
Figure S2). 
In patients initiated on prasugrel/ticagrelor, de-escalation to clopidogrel in UM/RM/NMs 
was associated with no difference in risk of experiencing either a MACCE or bleeding event 
compared to those continued on alternative therapy (21.3 vs. 19.3 events per 100 patient-years, 
respectively; adjusted HR 1.13, 95% CI 0.51-2.34, p=0.751). No significant difference was 
observed when de-escalation was compared to either IM/PMs (adjusted HR 1.35, 95% CI 0.54-
3.27, p=0.511) or UM/RM/NMs continued on alternative therapy (adjusted HR 0.99, 95% CI 




difference in risk of MACCE alone compared to continued alternative therapy (adjusted HR 
0.93, 95% CI 0.35-2.19, p=0.878). Moreover, no significant difference in risk of bleeding events 
was observed across groups (Table 2, Figure S2).  
Secondary analyses in patients with an ACS indication for PCI demonstrated similar 
results with the overall study population (Figure S3). In ACS patients initiated on alternative 
therapy, the risk of experiencing either a MACCE or bleeding event (adjusted HR 1.38, 95% CI 
0.56-3.15, p=0.461) or MACCE alone (adjusted HR 1.00, 95% CI 0.31-2.77, p=0.998) was not 
significantly different in UM/RM/NMs de-escalated to clopidogrel compared to those continued 
on alternative therapy. 
 
Time to Switch in P2Y12 Inhibitor Therapy. The timing of escalation and de-escalation varied, 
but de-escalation to clopidogrel occurred significantly later after PCI than escalation to 
prasugrel/ticagrelor (20 [2-39] vs. 4 [2-17] days, respectively, p=0.001). Accordingly, escalation 
occurred more frequently within 7 days (64.3% vs. 38.1%, p<0.001) and 30 days (85.2% vs. 
58.3%, p<0.001) after PCI than de-escalation, respectively. When evaluated exclusively in 
IM/PMs and UM/RM/NMs, respectively, time to de-escalation in UM/RM/NMs occurred 











The current study evaluated the frequency and timing of antiplatelet therapy escalation 
and de-escalation, and clinical outcomes in PCI patients following the implementation of a 
genotype-guided selection strategy in a real-world setting. Results illustrated that CYP2C19-
guided escalation and de-escalation were both common, and de-escalation from 
prasugrel/ticagrelor to clopidogrel in UM/RM/NMs occurred significantly later after PCI than 
escalation from clopidogrel to prasugrel/ticagrelor in IM/PMs. In patients initiated on 
clopidogrel, continuation of clopidogrel in IM/PMs was associated with a significantly higher 
risk of MACCE compared to genotype-guided escalation to alternative therapy. In patients 
initiated on prasugrel or ticagrelor, however, genotype-guided de-escalation to clopidogrel in 
UM/RM/NMs was associated with no difference in MACCE risk compared to those who 
continued alternative therapy. Taken together, these data illustrate that genotype-guided 
escalation to prasugrel or ticagrelor mitigates the risk of adverse cardiovascular outcomes 
conferred by clopidogrel use in CYP2C19 nonfunctional allele carriers, and that use of genotype 
to selectively guide de-escalation to clopidogrel in patients without a CYP2C19 nonfunctional 
allele appeared safe and effective. 
Clopidogrel, prasugrel and ticagrelor exhibit distinct pharmacological characteristics, and 
selection of the optimal antiplatelet therapy is a patient-centric, multifactorial clinical decision. 
Accordingly, numerous questions surrounding P2Y12 inhibitor switching have emerged.11,12 
Several prospective registry studies and post-hoc observational analyses have described the 
frequency and clinical impact of empiric (non-guided) antiplatelet switching;13–18 however, 
varying definitions of switching as well as regional and temporal differences in prescribing 




discharge switch frequencies were 12% and 8%, respectively,14,15 while the ACTION-GWTG 
and CathPCI Registry reported in-hospital switching at 6%, with considerable fluctuations across 
the study period.17 In-hospital switches were primarily escalation to prasugrel/ticagrelor,14,17 
while post-discharge switches were primarily de-escalation to clopidogrel.17 Despite the 
emergence of CYP2C19-guided antiplatelet selection in clinical practice,22 the frequency and 
timing of genotype-guided escalation and de-escalation has not been well-described. In our 
study, the frequency of genotype-guided switching after PCI was common (19%), and more 
frequent in ACS patients (22%) compared to non-ACS/elective PCI patients (14%). Although the 
frequency of switching in our study was comparable to multicenter U.S. registries that did not 
include genotyping, we observed that availability of a CYP2C19 genotype result significantly 
increased the likelihood of a switch occurring, and that switch direction was driven by the 
genotype result.  
CYP2C19 genotyping has been successfully implemented into clinical practice at a 
number of institutions.22,27,31–33 Given the historical use of clopidogrel as first-line therapy, early 
genotype-guided strategies and recommendations focused on escalation of IM/PMs to alternative 
therapy.3,22 In our study, approximately one-half of IM/PMs initiated on clopidogrel were 
escalated to alternative therapy in accordance with the genotype-guided algorithm. Furthermore, 
our results demonstrate that failure to escalate CYP2C19 nonfunctional allele carriers to 
alternative therapy is associated with adverse cardiovascular outcomes. These data are consistent 
with the multicenter Implementing GeNomics In PracTicE (IGNITE) Network investigation, a 
multicenter randomized clinical trial in Europe, and a single-center nonrandomized trial in 




alternative therapy reduces risk of major atherothrombotic events without increasing risk of 
major bleeding.19,20,34  
Although important, CYP2C19 genotype is one of multiple factors considered when 
prescribing a P2Y12 inhibitor. Various clinical factors, most notably risk factors for bleeding, are 
associated with continued clopidogrel use in IMs.26 Due to the higher risk of MACCE conferred 
by clopidogrel use in CYP2C19 nonfunctional allele carriers, particularly during the first 30 days 
after PCI,35,36 these results suggest that placing greater weight on an IM/PM result during the 
prescribing decision may be warranted. Although no difference in risk of clinically significant 
bleeding events was observed across groups, these results should be interpreted with caution 
since patients with higher underlying bleeding risk are more frequently prescribed clopidogrel. 
Furthermore, bleeding event rates were low and larger sample sizes are needed. The clinical 
benefit of genotype-guided antiplatelet therapy in patients undergoing non-ACS/elective PCI 
also remains unclear and requires further study. Low MACCE rates in elective PCI patients 
precluded investigation of outcomes in the current study. Two large randomized trials with 
results expected in 2020, TAILOR-PCI (NCT01742117) in elective and ACS PCI patients and 
POPULAR-Genetics (NCT01761786) in STEMI PCI patients, are examining the clinical utility 
of genotype-guided antiplatelet therapy and will provide insight into these gaps in evidence.29,37 
Efficiently and sustainably operationalizing CYP2C19 genotype-guided strategies in real-
world settings can be constrained by logistical challenges.22 Barriers include on-site availability 
of genotype tests, turnaround time, patient and provider education, and the lack of clinical 
decision support tools to report results. Due to the higher risk of MACCE during the early post-
PCI period, operational inefficiencies that delay genotype-guided escalation to alternative 




to clopidogrel in patients without a CYP2C19 nonfunctional allele after the early post-PCI period 
offers a practical solution to these challenges, and thus has emerged as a new strategy for 
genotype-guided antiplatelet therapy. 
Use of prasugrel or ticagrelor early after PCI, followed by de-escalation to clopidogrel 
maintenance therapy, has become more common in clinical practice.11,12 This is likely due to 
updated clinical practice guidelines recommending preferential use of prasugrel/ticagrelor after 
PCI in ACS patients,2 and the higher bleeding risks, discontinuation rates, and costs associated 
with these agents during chronic therapy.10–12 However, there are conflicting clinical outcomes 
data with an empiric (non-guided) de-escalation approach, with very early de-escalation to 
clopidogrel after ACS increasing risk of recurrent atherothrombotic events.16,24 The TROPICAL-
ACS randomized trial recently showed that a de-escalation strategy guided by platelet function 
testing (PFT) was non-inferior to universal prasugrel treatment in the prevention of major 
atherothrombotic or bleeding events after ACS and PCI.25 However, PFT must be completed 
during treatment, which may not be feasible in a real-world setting. In the genotyping substudy, 
CYP2C19 nonfunctional alleles were an independent predictor of high platelet reactivity in 
clopidogrel-treated patients, suggesting that CYP2C19 testing might be useful in selecting 
patients for de-escalation.38 As genotyping can be done a priori, it may represent a more 
practical approach for guided de-escalation in the outpatient setting than PFT; however, the 
impact of using genotype to guide de-escalation on clinical outcomes had not been evaluated 
until the present study.  
In our study, approximately one-third of UM/RM/NMs initiated on alternative therapy 
were de-escalated to clopidogrel. The timing of de-escalation after PCI varied across patients, 




UM/RM/NMs was associated with no significant difference in MACCE risk compared to 
continuation of prasugrel/ticagrelor. Moreover, no significant differences were observed in high-
risk patients with an ACS indication for PCI. While these results suggest that a genotype-guided 
de-escalation strategy is safe and effective in a real-world setting, our sample size was limited 
and should be interpreted with caution until validated in larger, multicenter populations. 
Likewise, a randomized trial of genotype-guided de-escalation may ultimately be of value. Our 
results provide the foundation for these future studies. 
We also observed that UM/RM/NMs initiated and continued on clopidogrel appeared to 
exhibit a moderately higher risk of MACCE compared to IM/PMs escalated to alternative 
therapy, albeit to a significantly lesser degree than IM/PMs continued on clopidogrel. This 
suggests there are important gaps in evidence surrounding the key clinical and genetic factors 
that contribute to clopidogrel effectiveness in patients without a CYP2C19 *2 or *3 
nonfunctional allele. For instance, only the *2, *3 and *17 alleles were genotyped. Additional 
nonfunctional CYP2C19 variant alleles (*4-*8) assigned to IM/PM phenotypes,3 although rare, 
were not evaluated, which is a limitation. Furthermore, inter-individual variation in the aspirin’s 
antiplatelet effects may influence outcomes after PCI.39 Additional studies are needed to 
determine whether genetic factors beyond CYP2C19 should be used to optimize antiplatelet 
therapy.  
It is important to acknowledge several limitations with our study. First, data collection 
was completed retrospectively via EHR abstraction. Thus, factors that contributed to antiplatelet 
selection and switching could not be conclusively determined. Second, genotype-guided therapy 
was not randomized and a standardized protocol for the timing of de-escalation after PCI was not 




cannot attribute cause-and-effect or exclude the influence of bias to the observed associations 
between genotype-guided escalation and de-escalation and clinical outcomes. Although 
covariate-adjusted and stratified analysis were conducted to lessen the potential confounding 
effects related to baseline differences observed across CYP2C19-antiplatelet therapy groups, 
such as diabetes and bleeding risk factors, socioeconomic factors were not evaluated and residual 
confounding may remain. Thus, the magnitude of the observed associations should be interpreted 
with caution. Lastly, these data reflect the experience with genotype-guided therapy at a single-
center, and may not be generalizable to other settings and populations. For instance, the low 
utilization of ticagrelor in our cohort does not reflect contemporary prescribing patterns of 
increased ticagrelor use.9 Future studies in more diverse populations are warranted. 
In summary, use of a CYP2C19-guided antiplatelet therapy strategy after PCI in a real-
world setting commonly necessitates both escalation of nonfunctional allele carriers to 
alternative therapy, and de-escalation of patients without a nonfunctional allele to clopidogrel. 
Genotype-guided escalation to prasugrel/ticagrelor mitigates the risk of adverse cardiovascular 
outcomes conferred by continued clopidogrel use in CYP2C19 nonfunctional allele carriers. In 
addition, early use of prasugrel/ticagrelor followed by genotype-guided de-escalation to 
clopidogrel maintenance therapy in those without a CYP2C19 nonfunctional allele appears to be 
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Table 1. Ischemic cardiovascular and bleeding event risk by CYP2C19 status and P2Y12 inhibitor maintenance therapy in 
patients initiated on clopidogrel during the index PCI (n=601). 
Clinical outcome by Event Event rate Log-rank P‡ Log-rank P‡ Adjusted HR P-value 
CYP2C19 phenotype–selected P2Y12 inhibitor No. (%)* (per 100 pt-yrs)†  (unadjusted) (adjusted) (95% CI) 
MACCE or clinically significant bleeding events 
 Continue Clopidogrel (IM/PM) 24 (27.6%) 51.8   2.89 (1.44-6.13) 0.003 
 Continue Clopidogrel (UM/RM/NM) 74 (17.5%) 26.6   1.37 (0.76-2.70) 0.304 
 Escalation to Prasugrel/Ticagrelor (IM/PM) 12 (13.3%) 19.4 P=0.007 P=0.003 Reference  
MACCE 
 Continue Clopidogrel (IM/PM)** 23 (26.4%) 49.5   5.72 (2.41-15.8) <0.001 
 Continue Clopidogrel (UM/RM/NM) 59 (13.9%) 20.9   2.27 (1.04-5.96) 0.038 
 Escalation to Prasugrel/Ticagrelor (IM/PM) 6 (6.7%) 9.5 P<0.001 P<0.001 Reference  
Clinically significant bleeding events 
 Continue Clopidogrel (IM/PM)** 2 (2.3%) 4.3   0.46 (0.07-2.07) 0.329 
 Continue Clopidogrel (UM/RM/NM) 20 (4.7%) 7.2   0.64 (0.26-1.81) 0.378 
 Escalation to Prasugrel/Ticagrelor (IM/PM) 6 (6.7%) 9.7 P=0.587 P=0.559 Reference  
*Data are presented as the number (%) of patients in each group that experienced the event over 12 months of follow-up after the index PCI. 
†The event rate was calculated as the number of events per 100 patient-years of follow-up. 
‡Unadjusted and covariate adjusted log-rank P-values across the three CYP2C19-antiplatelet strata. The small subset of 11 patients with a 
CYP2C19 UM/RM/NM phenotype that were escalated to alternative (prasugrel or ticagrelor) therapy were not included in the analysis. 




Table 2. Ischemic cardiovascular and bleeding event risk by CYP2C19 status and P2Y12 inhibitor maintenance therapy in patients 
initiated on prasugrel or ticagrelor during the index PCI (n=312). 
Clinical outcome by Event Event rate Log-rank P‡ Log-rank P‡ Adjusted HR P-value 
CYP2C19 phenotype–selected P2Y12 inhibitor No. (%)* (per 100 pt-yrs)†  (unadjusted) (adjusted) (95% CI) 
MACCE or clinically significant bleeding events 
 De-escalation to Clopidogrel (UM/RM/NM) 10 (14.5%) 21.3   1.35 (0.54-3.27) 0.511 
 Continue Prasugrel/Ticagrelor (UM/RM/NM) 17 (13.0%) 20.4   1.36 (0.63-3.00) 0.438 
 Continue Prasugrel/Ticagrelor (IM/PM) 13 (11.6%) 17.9 P=0.884 P=0.710 Reference  
MACCE 
 De-escalation to Clopidogrel (UM/RM/NM) 7 (10.1%) 14.8   1.07 (0.36-3.03) 0.895 
 Continue Prasugrel/Ticagrelor (UM/RM/NM) 14 (10.7%) 16.2   1.27 (0.54-3.09) 0.590 
 Continue Prasugrel/Ticagrelor (IM/PM) 10 (8.9%) 13.5 P=0.906 P=0.854 Reference  
Clinically significant bleeding events 
 De-escalation to Clopidogrel (UM/RM/NM) 4 (5.8%) 8.5   2.67 (0.53-14.9) 0.228 
 Continue Prasugrel/Ticagrelor (UM/RM/NM) 6 (4.6%) 7.2   2.41 (0.57-12.7) 0.239 
 Continue Prasugrel/Ticagrelor (IM/PM) 3 (2.7%) 4.1 P=0.608 P=0.438 Reference  
*Data are presented as the number (%) of patients in each group that experienced the event over 12 months of follow-up after the index PCI. 
†The event rate was calculated as the number of events per 100 patient-years of follow-up. 
‡Unadjusted and covariate adjusted log-rank P-value across the three CYP2C19-antiplatelet strata. The small subset of 4 patients with a 





Figure 1. P2Y12 inhibitor maintenance therapy selection and switching by CYP2C19 status. 
(A) Maintenance therapy distribution by switch status in genotyped patients (n=1063). Left 
panel: initiated and continued on clopidogrel or alternative therapy (i.e., not switched). Right 
panel: switched to alternative therapy (escalation) or to clopidogrel (de-escalation). *Two 
switched from prasugrel to ticagrelor; one from ticagrelor to prasugrel. (B) Distribution of 





























































Figure 2. Cardiovascular or bleeding events over 12 months following PCI by CYP2C19 
status and initial and maintenance P2Y12 inhibitor therapy. (A) Study population summary 
by initial P2Y12 inhibitor, CYP2C19 phenotype, and maintenance therapy. (B, C) Kaplan-Meier 
curves describing cumulative event rates for the composite of either a MACCE or bleeding event 
after stratifying by initial therapy: (B) clopidogrel, (C) prasugrel/ticagrelor. Data shown across 
IM/PMs prescribed clopidogrel (Clop-IM/PM), IM/PMs prescribed prasugrel/ticagrelor (Alt-
IM/PM), UM/RM/NMs prescribed clopidogrel (Clop-U/R/NM), and UM/RM/NMs prescribed 
prasugrel/ticagrelor (Alt-U/R/NM). *Due to rare occurrence, UM/RM/NMs escalated to 
prasugrel/ticagrelor and IMs de-escalated to clopidogrel were not included in the outcome 
analysis. The unadjusted log rank P-value is provided. 
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Clop-IM/PM 87 61 48 39 3
Clop-U/R/NM 424 341 311 226 26
Alt-IM/PM 90 79 65 52 7
Total 601 481 424 317 36
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Number at risk
Clop-U/R/NM 69 61 53 41 3
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Figure 3. Time to escalation and de-escalation of P2Y12 inhibitor therapy by CYP2C19 
status. The cumulative frequency of initiating prasugrel or ticagrelor maintenance therapy in 
IM/PMs (N=329) and UM/RM/NMs (N=734) is presented as a function of time following the 
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Supplemental Table S1. Study population characteristics by initial P2Y12 inhibitor therapy at 
index PCI. 
 
Characteristic Overall Clopidogrel Prasugrel/ P-value* 
   Ticagrelor  
N   1493 1066 (71.4%) 427 (28.6%)  
Age  63.2 ± 11.9 65.4 ± 12.0 57.8 ± 9.7 <0.001 
Male  1007 (67.5%) 685 (64.3%) 322 (75.4%) <0.001 
African American 300 (20.1%) 227 (21.3%) 73 (17.1%) 0.064 
Obese (BMI ≥ 30) 657 (44.0%) 453 (42.5%) 204 (47.8%) 0.064 
Current smoker  408 (27.3%) 267 (25.1%) 141 (33.0%) 0.002 
Hypertension 1258 (84.3%) 936 (87.8%) 322 (75.4%) <0.001 
Diabetes 635 (42.5%) 495 (46.4%) 140 (32.8%) <0.001 
Peripheral vascular disease 182 (12.2%) 158 (14.8%) 24 (5.6%) <0.001 
Atrial fibrillation 147 (9.9%) 129 (12.1%) 18 (4.2%) <0.001 
Previous myocardial infarction 404 (27.1%) 314 (29.5%) 90 (21.1%) <0.001 
Elevated bleeding risk† 585 (39.2%) 512 (48.0%) 73 (17.1%) <0.001 
 Age ≥ 75 268 (18.0%) 256 (24.0%) 12 (2.8%) <0.001 
 Weight <60 kg 91 (6.1%) 82 (7.7%) 9 (2.1%) <0.001 
 Previous TIA or stroke 140 (9.4%) 129 (12.1%) 11 (2.6%) <0.001 
 Previous significant bleeding 123 (8.2%) 98 (9.2%) 25 (5.9%) 0.029 
 End-stage renal disease 59 (4.0%) 52 (4.9%) 7 (1.6%) 0.002 
 Anticoagulant at discharge 100 (6.7%) 82 (7.7%) 18 (4.2%) 0.011 
Previous coronary artery stent 561 (37.6%) 452 (42.4%) 109 (25.5%) <0.001 
Indication for PCI 
Non-ACS/elective 682 (45.7%) 556 (52.2%) 126 (29.5%) 
Acute coronary syndrome 811 (54.3%) 510 (47.8%) 301 (70.5%) <0.001 
Stent placement at index PCI 
 LAD artery stent 621 (41.6%) 402 (37.7%) 219 (51.3%) <0.001 
 Multiple vessels stented 194 (13.0%) 132 (12.4%) 62 (14.5%) 0.272 
 Drug-eluting stent 1265 (84.7%) 890 (83.5%) 375 (87.8%) 0.042 
Medications at discharge 
 Aspirin 1471 (98.5%) 1050 (98.5%) 421 (98.6%) 0.889 
 ACE inhibitor or ARB 1020 (68.3%) 719 (67.5%) 301 (70.5%) 0.252 
 Beta-blocker 1273 (85.3%) 901 (84.5%) 372 (87.1%) 0.196 
 Statin 1402 (93.9%) 991 (93.0%) 411 (96.3%) 0.012 
  
Data are presented as the mean ± standard deviation and number (percentage). 
*P-value reported corresponds to comparisons across the clopidogrel vs. prasugrel or ticagrelor strata.  
†Elevated bleeding risk is a composite variable defined as one or more of the following: age ≥75 years; weight <60 kg; 
previous TIA or stroke event; previous significant bleeding event; current end stage renal disease requiring dialysis; or, 





Supplemental Table S2. Genotype Testing Characteristics and P2Y12 Inhibitor Selection by Indication for PCI. 
 
Characteristic Overall ACS Non-ACS/elective P-value* 
N    1493 811 682  
CYP2C19 genotype obtained 1063 (71.2%) 635 (78.3%) 428 (62.8%) <0.001 
 Genotype at index PCI admission† 971 (65.0%) 601 (74.1%) 370 (54.3%) <0.001 
  Time to genotype result from:  
  Genotype order 1 [1-1] 1 [1-1] 1 [1-1] 0.589 
  Index PCI procedure 1 [1-2] 1 [1-2] 1 [1-2] 0.238 
  Results returned within 1-day of PCI 671 (69.1%) 404 (67.2%) 267 (72.2%) 0.104 
 Maintenance Therapy Selection 
  All Genotyped Patients N=1063 N=635 N=428 
  Prasugrel/ticagrelor 402 (37.8%) 275 (43.3%) 127 (29.7%)  
  Clopidogrel 661 (62.2%) 360 (56.7%) 301 (70.3%) <0.001 
  Escalation to prasugrel/ticagrelor 115 (10.8%) 72 (11.3%) 43 (10.0%) 0.505 
  De-escalation to clopidogrel 84 (7.9%) 68 (10.7%) 16 (3.7%) <0.001 
  CYP2C19 IM/PM‡  N=329 N=192 N=137 
  Prasugrel/ticagrelor 226 (68.7%) 145 (75.5%) 81 (59.1%)  
  Clopidogrel 103 (31.3%) 47 (24.5%) 56 (40.9%) 0.002 
  Escalation to prasugrel/ticagrelor 101 (30.7%) 60 (31.3%) 41 (29.9%) 0.797 
  De-escalation to clopidogrel 7 (2.1%) 3 (1.6%) 4 (2.9%) 0.405 
  CYP2C19 UM/RM/NM‡  N=734 N=443 N=291  
  Prasugrel/ticagrelor 176 (24.0%) 130 (29.3%) 46 (15.8%)  
  Clopidogrel 558 (76.0%) 313 (70.7%) 245 (84.2%) <0.001 
  Escalation to prasugrel/ticagrelor 14 (1.9%) 12 (2.7%) 2 (0.7%) 0.036 
  De-escalation to clopidogrel 77 (10.5%) 65 (14.7%) 12 (4.1%) <0.001 
 
Data are presented as median [25%–75%] and count (percentage).  
* P-value reported corresponds to comparisons across the ACS vs. non-ACS/elective strata.  
† Patients with CYP2C19 testing ordered at the index PCI encounter. Ninety-two (8.7%) of patients with a genotype result available had CYP2C19 testing completed at a prior PCI, with 
results already available in the medical record. 






Supplemental Table S3. Population Characteristics by CYP2C19 Status and P2Y12 Inhibitor Maintenance Therapy in Patients 
Initiated on Clopidogrel During the Index PCI Procedure. 
 
 Continue Escalation to Continue  
Characteristic Clopidogrel Prasugrel or Ticagrelor  Clopidogrel   P-value* 
 (IM/PM) (IM/PM) (UM/RM/NM)  
N    87 90 424 
Age   64.7 ± 11.2 63.2 ± 11.9 65.2 ± 12.8 0.369 
Male   60 (69.0%) 60 (66.7%) 253 (59.7%) 0.161 
African American 23 (26.4%) 13 (14.4%) 86 (20.3%) 0.138 
Obese (BMI ≥30 kg/m2) 38 (43.7%) 37 (41.1%) 172 (40.6%) 0.866 
Current smoker  23 (26.4%) 26 (28.9%) 111 (26.2%) 0.871 
Hypertension  81 (93.1%) 66 (73.3%) 364 (85.9%) 0.001 
Diabetes  49 (56.3%) 31 (34.4%) 183 (43.2%) 0.012 
Peripheral vascular disease 12 (13.8%) 15 (16.7%) 55 (13.0%) 0.662 
Atrial fibrillation 12 (13.8%) 8 (8.9%) 52 (12.3%) 0.555 
Previous myocardial infarction 32 (36.8%) 29 (32.2%) 122 (28.8%) 0.318 
Elevated bleeding risk† 44 (50.6%) 32 (35.6%) 214 (50.5%) 0.031 
 Age ≥75 years 18 (20.7%) 19 (21.1%) 106 (25.0%) 0.554 
 Weight <60 kg 5 (5.8%) 3 (3.3%) 45 (10.6%) 0.048 
 Previous TIA or stroke 10 (11.5%) 7 (7.8%) 47 (11.1%) 0.607 
 Previous significant bleeding 10 (11.5%) 11 (12.2%) 42 (9.9%) 0.770 
 End-stage renal disease 4 (4.6%) 2 (2.2%) 27 (6.4%) 0.303 
 Anticoagulant at discharge 9 (10.3%) 1 (1.1%) 32 (7.6%) 0.020 
Previous coronary artery stent 41 (47.1%) 33 (36.7%) 183 (43.2%) 0.352 
ACS indication for index PCI 38 (43.7%) 52 (57.8%) 231 (54.5%) 0.123 
Stent placement at index PCI 
 Multple vessels stented 10 (11.5%) 9 (10.0%) 48 (11.3%) 0.929 
 Drug-eluting stent 73 (83.9%) 74 (82.2%) 346 (81.6%) 0.874 
Medications at discharge 
 Aspirin  87 (100%) 89 (98.9%) 418 (98.6%) 0.839 
 ACE inhibitor or ARB 62 (71.3%) 61 (67.8%) 284 (67.0%) 0.735 
 Beta-blocker 75 (86.2%) 70 (77.8%) 367 (86.6%) 0.122 
 Statin  83 (95.4%) 84 (93.3%) 396 (93.4%) 0.866 
 
* P-value compares the clopidogrel IM/PM, alternative IM/PM, and clopidogrel UM/RM/NM groups. The small subset of 11 patients with a CYP2C19 UM/RM/NM phenotype that were 
escalated to alternative (prasugrel or ticagrelor) therapy were not included in the analysis. 
† Elevated bleeding risk is a composite variable defined as one or more of the following: age ≥75 years; weight <60 kg; previous TIA or stroke event; previous significant bleeding event; 




Supplemental Table S4. Population Characteristics by CYP2C19 Status and P2Y12 Inhibitor Maintenance Therapy in Patients 
Initiated on Alternative Therapy (Prasugrel or Ticagrelor) During the Index PCI Procedure.  
 
 Continue  De-escalation to Continue 
Characteristic Prasugrel or Ticagrelor   Clopidogrel  Prasugrel or Ticagrelor  P-value* 
 (IM/PM)  (UM/RM/NM) (UM/RM/NM) 
N    112  69 131  
Age   57.2 ± 10.6  58.5 ± 9.0 57.8 ± 8.3 0.635 
Male   89 (79.5%)  52 (75.4%) 100 (76.3%) 0.771 
African American 23 (20.5%)  10 (14.5%) 20 (15.3%) 0.461  
Obese (BMI ≥30 kg/m2) 52 (46.4%)  29 (42.0%) 62 (47.3%) 0.764 
Current smoker  35 (31.3%)  27 (39.1%) 42 (32.1%) 0.513 
Hypertension  80 (71.4%)  52 (75.4%) 90 (68.7%) 0.608 
Diabetes  27 (24.1%)  27 (39.1%) 43 (32.8%) 0.088 
Peripheral vascular disease 6 (5.4%)  4 (5.8%) 5 (3.8%) 0.792 
Atrial fibrillation 7 (6.3%)  5 (7.3%) 3 (2.3%) 0.159 
Previous myocardial infarction 25 (22.3%)  19 (27.5%) 18 (13.7%) 0.047 
Elevated bleeding risk† 32 (28.6%)  11 (15.9%) 12 (9.2%) <0.001 
 Age ≥75 years 3 (2.7%)  2 (2.9%) 2 (1.5%) 0.698 
 Weight <60 kg 4 (3.6%)  1 (1.5%) 2 (1.5%) 0.613 
 Previous TIA or stroke 3 (2.7%)  2 (2.9%) 2 (1.5%) 0.698 
 Previous significant bleeding 13 (11.6%)  2 (2.9%) 4 (3.1%) 0.014 
 End-stage renal disease 4 (3.6%)  2 (2.9%) 0 (0%) 0.060 
 Anticoagulant at discharge 11 (9.8%)  2 (2.9%) 4 (3.1%) 0.059 
Previous coronary artery stent 27 (24.1%)  16 (23.2%) 20 (15.3%) 0.174 
ACS indication for index PCI 79 (70.5%)  58 (84.1%) 100 (76.3%) 0.108  
Stent placement at index PCI 
 Multple vessels stented 13 (11.6%)  14 (20.3%) 22 (16.8%) 0.263 
 Drug-eluting stent 89 (79.5%)  61 (88.4%) 118 (90.1%) 0.053 
Medications at discharge 
 Aspirin  112 (100%)  69 (100%) 128 (97.7%) 0.243 
 ACE inhibitor or ARB 89 (79.5%)  48 (69.6%) 89 (67.9%)  0.105 
 Beta-blocker 103 (92.0%)  60 (87.0%) 114 (87.0%) 0.395 
 Statin  107 (95.5%)  68 (98.6%) 127 (97.0%) 0.601 
 
* P-value compares the alternative IM/PM, clopidogrel UM/RM/NM and alternative UM/RM/NM groups. The small subset of 4 patients with a CYP2C19 IM phenotype that were de-
escalated to clopidogrel therapy were not included in the analysis. 
† Elevated bleeding risk is a composite variable defined as one or more of the following: age ≥75 years; weight <60 kg; previous TIA or stroke event; previous significant bleeding event; 




Supplemental Figure S1. Algorithm for CYP2C19 Genotype-Guided Escalation and De-escalation of 
Antiplatelet Therapy Following PCI in High-Risk Patients. Following risk stratification during the index PCI 
procedure, initial antiplatelet therapy (clopidogrel, prasugrel or ticagrelor) is selected based on clinical factors and 
a CYP2C19 genotype test is ordered at the interventional cardiologist’s discretion. CYP2C19 genotype testing is 
recommended in high-risk patients (defined as a PCI for either an acute coronary syndrome or stable CAD with 
high-risk anatomic findings) and performed on-site during the PCI admission. Genotype results are reviewed by a 
pathologist and uploaded into the laboratory section of the electronic health record. The genotype result is then 
reviewed by a cardiologist and clinical pharmacist, and used to select the maintenance antiplatelet therapy. Options 
include (a) continuation of the initial agent, (b) escalation (switch clopidogrel to either prasugrel or ticagrelor), or 
(c) de-escalation (switch prasugrel or ticagrelor to clopidogrel). Alternative antiplatelet therapy is recommended to 
patients with a CYP2C19 intermediate metabolizer (IM) or poor metabolizer (PM) phenotype, in the absence of 
contraindications. In individuals with ultrarapid metabolizer (UM), rapid metabolizer (RM) or normal metabolizer 
(NM) phenotype, clopidogrel is recommended. However, selection of maintenance therapy and timing of a switch, 
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Supplemental Figure S2. Cardiovascular and Bleeding Events Over 12 Months Following PCI by 
CYP2C19 Status and Initial and Maintenance P2Y12 Inhibitor Therapy. Kaplan-Meier curves describing 
cumulative event rates for (A,B) MACCE and (C,D) clinically significant bleeding events. Analyses were 
completed after stratifying by initial antiplatelet therapy at the index PCI: (A,C) clopidogrel and (B,D) 
prasugrel/ticagrelor. Data are shown across CYP2C19 phenotype and antiplatelet therapy strata: intermediate or 
poor metabolizers prescribed clopidogrel (Clop-IM/PM), IM/PMs prescribed alternative therapy (Alt-IM/PM), 
ultrarapid, rapid or normal metabolizers prescribed clopidogrel (Clop-U/R/NM), and U/R/NMs prescribed 
alternative therapy (Alt-U/R/NM). *CYP2C19 UM/RM/NMs escalated to alternative therapy and IMs de-escalated 
to clopidogrel were not included in the outcome analysis. The unadjusted log rank P-value across the three groups, 
the number (%) that experienced an event over 12 months of follow-up, the event rate per 100 patient-years of 
follow-up, and the adjusted HR, 95% CI and P-value for the indicated between-group comparisons are provided. In 
panels B and C, the Alt-IM/PM and Alt-U/R/NM groups were combined into a single referent group for comparison 
with Clop-U/R/NM (de-escalation). 
 
Number at risk
Clop-IM/PM 87 62 48 39 3
Clop-U/R/NM 424 348 317 229 26
Alt-IM/PM 90 79 67 54 8
Total 601 489 432 322 37




Clop-IM/PM 87 61 48 39 3
Clop-U/R/NM 424 341 311 226 26
Alt-IM/PM 90 79 65 52 7
Total 601 481 424 317 36
D
Number at risk
Clop-U/R/NM 68 61 54 41 3
Alt-U/R/NM 132 109 95 75 6
Alt-IM/PM 111 98 79 53 6
Total 311 268 228 169 15
Initial antiplatelet therapy - alternative
Number at risk
Clop-U/R/NM 69 61 53 41 3
Alt-U/R/NM 131 105 93 73 6
Alt-IM/PM 112 97 80 52 5
Total 312 263 226 166 14
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- IM/PM 23 (26.4%) 49.5 5.72 (2.41-15.81) <0.001
Clop- U/R/NM 59 (13.9%) 20.9 2.27 (1.04-5.96) 0.038
Alt- IM/PM 6 (6.7%) 9.5 Reference
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- U/R/NM 7 (10.1%) 14.8 0.93 (0.35-2.19) 0.878
Alt- U/R/NM 14 (10.7%) 16.2
Alt- IM/PM 10 (8.9%) 13.5
Reference
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- IM/PM 2 (2.3%) 4.3 0.46 (0.07-2.07) 0.329
Clop- U/R/NM 20 (4.7%) 7.2 0.64 (0.26-1.81) 0.378
Alt- IM/PM 6 (6.7%) 9.7 Reference
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- U/R/NM 4 (5.8%) 8.5 1.53 (0.40-4.92) 0.503
Alt- U/R/NM 6 (4.6%) 7.2
Alt- IM/PM 3 (2.7%) 4.1
Reference
MACCE
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Supplemental Figure S3. Cardiovascular or Bleeding Events Over 12 Months Following PCI by 
CYP2C19 Status and P2Y12 Inhibitor Therapy in Patients with an ACS Indication for the Index PCI 
Procedure. (A) Study population summary by initial P2Y12 inhibitor therapy, CYP2C19 phenotype, and 
maintenance therapy in ACS patients (N=569). (B, C) Kaplan-Meier curves describing cumulative event rates for 
the composite of either MACCE or clinically significant bleeding events after stratifying by initial antiplatelet 
therapy at the index PCI: (B) clopidogrel and (C) prasugrel/ticagrelor. Data are shown across CYP2C19 phenotype 
and antiplatelet therapy strata: intermediate or poor metabolizers prescribed clopidogrel (Clop-IM/PM), IM/PMs 
prescribed alternative therapy (Alt-IM/PM), ultrarapid, rapid or normal metabolizers prescribed clopidogrel (Clop-
U/R/NM), and U/R/NMs prescribed alternative therapy (Alt-U/R/NM). *CYP2C19 UM/RM/NMs escalated to 
alternative therapy and IMs de-escalated to clopidogrel were not included in the outcome analysis. The unadjusted 
log rank P-value across the three groups, the number (%) that experienced an event over 12 months of follow-up, 
the event rate per 100 patient-years of follow-up, and the adjusted HR, 95% CI and P-value for the indicated 
between-group comparisons are provided. In panel C, the Alt-IM/PM and Alt-U/R/NM groups were combined into 





Clop-IM/PM 38 23 19 14 2
Clop-U/R/NM 231 175 160 111 14
Alt-IM/PM 52 41 35 28 6
Total 321 239 214 153 22
Number at risk
Clop-U/R/NM 58 50 42 34 2
Alt-U/R/NM 100 77 73 60 6
Alt-IM/PM 79 69 57 38 4
Total 237 196 172 132 12
ACS patients initiated on Clopidogrel
N=330 (58.0%)
ACS patients initiated on Pras/Ticag
N=239 (42.0%)
ACS patients who underwent 
PCI and CYP2C19 genotyping
N=635




ACS patients with follow-up 
available after the index PCI
N=569
Patients without follow-up 
available in the medical record 
after the index PCI admission
N=66 (10.4%)




































Clop - IM/PM Alt - IM/PM
(escalation)
Clop - U/R/NM Clop - U/R/NM
(de-escalation)
Alt - U/R/NM Alt - IM/PM
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- U/R/NM 9 (15.5%) 23.7 1.38 (0.56-3.15) 0.461
Alt- U/R/NM 13 (13.0%) 20.2
Alt- IM/PM 8 (10.1%) 15.5
Group Events Event Rate Adjusted HR P-value
No. (%) (per 100 pt-yrs) (95% CI)
Clop- IM/PM 17 (44.7%) 98.5 4.09 (1.70-10.91) 0.001
Clop- U/R/NM 52 (22.5%) 36.8 1.62 (0.76-4.02) 0.223
Alt- IM/PM 7 (13.5%) 21.0 Reference
Reference
MACCE or clinically significant bleeding
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